On January 18, Shandong Lukang Pharmaceutical Co.Ltd(600789) announced that the four specifications of penicillin sodium for injection of the company had passed the consistency evaluation of generic drug quality and efficacy, Shandong Lukang Pharmaceutical Co.Ltd(600789) became the first "evaluated" enterprise of this variety.
Penicillin is suitable for various infections caused by sensitive bacteria, such as abscess, bacteremia, pneumonia and endocarditis. Penicillin can kill all kinds of bacteria, but it has little toxicity to human body. Therefore, penicillin is the most widely used antibiotic in clinic so far.
According to the database of yaozhi.com, there are 113 approvals of penicillin sodium for injection and 23 manufacturers in China. According to the data of China National Chemical Engineering Co.Ltd(601117) Pharmaceutical Industry Association, the sales of penicillin sodium in China in 2020 was about 570 million yuan, and the sales in the first three quarters of 2021 was about 390 million yuan.
Shandong Lukang Pharmaceutical Co.Ltd(600789) in the first three quarters of 2021, the sales volume of the product was about 137 million yuan. The evaluated penicillin sodium for injection included four specifications: 0.48g (800000 units), 0.96g (1.6 million units), 2.4G (4 million units) and 4.8g (8 million units). Since the consistency evaluation, Shandong Lukang Pharmaceutical Co.Ltd(600789) the R & D cost for this variety has been about 6.5426 million yuan. Shandong Lukang Pharmaceutical Co.Ltd(600789) said that the first evaluation of this variety will help the company expand its market share.
